Losing your eyesight is one of the most frightening possibilities associated with getting older, especially when the damage affects the nerves responsible for sending visual information to the brain. For millions of people living with glaucoma and other age-related eye conditions, existing treatments can help slow the disease, but restoring vision that has already been lost remains a major challenge. Now, scientists are testing an experimental gene therapy designed to help aging cells in the eye recover some of their function, raising new questions about whether certain forms of vision loss could eventually become more treatable.
The treatment, known as ER-100, is being developed by Life Biosciences and uses a technique called epigenetic reprogramming. In an early human trial involving three participants, researchers observed preliminary improvements in visual field testing in two people. The findings are encouraging enough to justify further investigation, although the study is still in its early stages and cannot establish whether the treatment will reliably restore vision. The research builds on earlier experiments involving mice and could eventually influence how scientists approach diseases associated with aging.
Scientists Are Testing a New Approach to Vision Loss
The experimental treatment targets retinal ganglion cells, which play a critical role in transmitting visual information from the eye to the brain. These specialized nerve cells are particularly important in glaucoma, a disease that damages the optic nerve and can gradually reduce a person’s peripheral vision. As the condition progresses, affected individuals may lose the ability to see objects outside their direct line of sight, sometimes without noticing significant changes during the early stages.
Existing glaucoma treatments generally focus on reducing pressure inside the eye to slow further damage. Eye drops, laser procedures and surgery can help manage the condition, but they cannot reliably restore vision already lost through permanent nerve damage. ER-100 takes a different approach by investigating whether surviving cells can recover some of their function after experiencing age-related changes. Rather than simply trying to slow deterioration, researchers are exploring whether it may be possible to influence the biological processes that contribute to declining cellular performance.
The company’s early clinical findings have drawn attention because they suggest that the treatment may affect measurable aspects of human vision. In its initial report, Life Biosciences said two of the three participants showed preliminary improvements in visual field testing. Sharon Rosenzweig-Lipson, the company’s chief scientific officer, said the observations were encouraging as the team continued advancing the experimental treatment. However, the number of participants remains extremely small, and further studies are needed to determine whether the improvements resulted from the therapy and whether they can be sustained over time.
What Happened During the First Human Trial?
The initial study was designed primarily to assess safety and tolerability, rather than prove that ER-100 could restore eyesight. Researchers administered the experimental therapy to three participants and monitored their responses during the early follow-up period. Life Biosciences reported that all three participants tolerated the initial dose through Day 56, with no serious adverse events or dose-limiting toxicities reported during that period. These early observations provide useful information, but a short follow-up period cannot establish the treatment’s long-term safety.
The visual field results provided another reason for researchers to continue investigating the approach. Visual field tests measure how well a person detects light at different positions within their field of vision, helping clinicians identify areas where sight may have weakened. In two participants, the company reported improvements across multiple test locations. At least 28% of the measured visual field points in each of those participants improved by more than four decibels, according to the company’s preliminary findings.
Although those measurements offer a possible signal of benefit, they should not be interpreted as proof that the treatment reverses glaucoma. Early clinical studies involve limited numbers of people, and visual testing can be affected by several factors. Larger trials will need to determine whether similar changes occur consistently, whether they represent meaningful improvements in daily life, and whether any benefits persist after treatment.
How Epigenetic Reprogramming Could Help Aging Cells
The science behind ER-100 centers on epigenetics, the system of biological mechanisms that helps regulate how genes are used inside cells. Your DNA contains genetic instructions, but cells do not activate every gene at the same time. Epigenetic processes help determine which instructions are active and how strongly they influence cellular behavior. As organisms age, changes in these regulatory systems can affect how well cells perform their normal functions, prompting scientists to investigate whether some of those changes can be reversed.
ER-100 uses three transcription factors known as OCT4, SOX2 and KLF4, collectively referred to as OSK. These proteins help regulate gene activity and are involved in cellular reprogramming. The treatment delivers genetic instructions that allow targeted cells to produce these factors under controlled conditions, with the goal of restoring certain youthful patterns of gene regulation. The approach aims to influence how cells function rather than replace a person’s DNA with an entirely new genetic sequence.
The therapy uses a modified viral delivery system to introduce the instructions into targeted cells. Participants in the trial also receive oral doxycycline for eight weeks to activate OSK expression. Researchers must carefully control this process because extensive cellular reprogramming can disrupt a cell’s identity and normal activity. The challenge is to encourage beneficial changes while avoiding unwanted effects, making safety testing essential before the technique can be considered for wider medical use.
Why Glaucoma Is So Difficult to Treat
Glaucoma refers to a group of eye diseases that damage the optic nerve, which carries visual information from the retina to the brain. Elevated pressure inside the eye is a major risk factor, although some people develop the disease even when their eye pressure falls within the usual range. The damage often begins with peripheral vision, meaning people may continue seeing clearly straight ahead while gradually losing their ability to detect objects around them.
One of the biggest difficulties is that glaucoma can develop without obvious early symptoms. People may not realize anything is wrong until noticeable changes appear, and some of the damage may already be permanent by that stage. Age, family history and certain medical conditions can influence an individual’s risk. Regular comprehensive eye examinations are therefore important, particularly for people with known risk factors or a family history of the disease.
Retinal ganglion cells are especially important because they transmit visual signals through long nerve fibers that contribute to the optic nerve. When these cells die or their connections become severely damaged, the visual system loses part of its ability to carry information to the brain. Human nervous tissue has limited capacity to replace certain damaged neurons, which explains why protecting existing cells remains central to glaucoma treatment. If epigenetic reprogramming eventually proves effective, it could offer another avenue for helping surviving cells function, although researchers have not yet established that ER-100 can reliably recover lost vision.
The Earlier Research That Led to ER-100
The treatment builds on research published in the journal Nature in 2020 by a team that included Harvard Medical School geneticist David Sinclair and lead author Yuancheng Lu. In experiments involving mice, researchers investigated whether the expression of three transcription factor genes could restore youthful characteristics in retinal ganglion cells. The findings provided preclinical evidence that partial cellular reprogramming could improve certain measures of visual function in animal models.
Those experiments helped establish the scientific rationale for investigating the technique in humans. However, successful results in mice do not guarantee that a treatment will be safe or effective in people. Differences in biology, disease progression and treatment response can influence whether findings from animal experiments translate into clinical benefits. The current human study represents an important step because researchers can begin assessing the approach under carefully monitored clinical conditions.
The company is also investigating ER-100 for non-arteritic anterior ischemic optic neuropathy, commonly known as NAION. This condition involves reduced blood supply to the optic nerve and can cause sudden vision loss. Studying the treatment across different optic nerve conditions may help researchers understand whether the approach has broader potential, but the evidence remains preliminary. Clinical testing will need to establish which patients, if any, could benefit and what risks the treatment may carry.
Could This Research Eventually Help Other Parts of the Body?
The eye provides a useful starting point for cellular reprogramming research because clinicians can measure aspects of visual function and monitor changes over time. Scientists can also examine certain structures of the eye directly, giving them ways to evaluate whether an experimental treatment appears to affect its intended targets. These features make eye diseases a practical setting for investigating therapies that aim to influence the biology of aging cells.
The underlying principle may also have applications beyond vision. Sinclair has discussed the possibility that age-related epigenetic changes occur across different tissues, meaning similar biological mechanisms could potentially be relevant elsewhere in the body. Life Biosciences has also described encouraging preclinical signals in other organs, including the liver. These findings provide a reason for further research, but they do not establish that the treatment will reverse aging throughout the human body.
Different organs have different functions and safety requirements, so a technique that affects retinal cells may not work in the same way elsewhere. Researchers must establish how the treatment behaves in each tissue, whether it creates unwanted changes and whether any benefits outweigh the risks. For now, the most relevant evidence concerns the biological rationale for ER-100 and the preliminary observations from its small human trial.
What You Can Do to Protect Your Eyesight Today
Although research into cellular reprogramming is advancing, ER-100 remains experimental and is not an established treatment for glaucoma. People concerned about their eyesight should continue relying on proven eye care rather than waiting for future therapies. Several practical steps can help identify eye problems earlier and support the management of existing conditions.
- Schedule comprehensive eye examinations. Glaucoma can develop before noticeable symptoms appear, so professional examinations can help identify changes early.
- Follow your prescribed treatment plan. If you have glaucoma, continue using prescribed medication and attending follow-up appointments, even when your vision feels normal.
- Know your family history. Tell your eye care professional if close relatives have glaucoma or other serious eye conditions.
- Seek urgent care for sudden symptoms. Sudden vision loss, severe eye pain or an abrupt change in eyesight requires prompt medical assessment.
- Discuss your individual risk factors. Your age, medical history and existing eye conditions can help determine which examinations and monitoring schedule are appropriate.
Healthy habits support general well-being, but they cannot replace treatment for glaucoma or reverse established optic nerve damage on their own. If you have concerns about changing vision, an eye care professional can help assess the cause and recommend appropriate next steps.
Researchers Still Need to Prove the Treatment Works
The early ER-100 findings offer a reason to investigate whether aging eye cells can recover some of their function through controlled epigenetic reprogramming. Improvements observed in two participants are worth studying further, but three participants and 56 days of initial observation cannot establish long-term effectiveness or prove that lost vision can be restored.
For people worried about age-related vision loss, the most useful approach is to protect their eyesight with established medical care while following the research as it develops. The possibility of helping damaged cells function again is scientifically interesting, but the next challenge is demonstrating that the therapy can deliver reliable, lasting benefits without unacceptable risks.
Sources:
- ClinicalTrials.gov. (n.d.-b). https://clinicaltrials.gov/study/NCT07290244?
- Farrand, M. (2026, October 8). Life Biosciences Announces First-in-Human Data from Ongoing Phase 1 Trial Evaluating ER-100 in Optic Neuropathies. Life Biosciences, Inc. https://www.lifebiosciences.com/life-biosciences-announces-first-in-human-data-from-ongoing-phase-1-trial-evaluating-er-100-in-optic-neuropathies/
